A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Adalimumab for the Induction and Maintenance of Clinical Remission in Chinese Patients With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein
收藏DataCite Commons2025-12-20 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003184/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study will evaluate the efficacy and safety of adalimumab induction and maintenance treatment in subjects with moderately to severely active Crohn's disease.
提供机构：
Vivli
创建时间：
2018-10-27
